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Among different clinical staphylococcal strains, linezolid resis-tance has mainly been mediated by mutations in the central
loop of domain V of 23S rRNA, with the change of G-to-T at
position 2576 (G2576T mutation) being the most prevalent.
However, linezolid resistance associated with mutations in ribo-
somal proteins has recently been described, and the precise role of
these mutations is under investigation. Many L3 mutations have
been associated with resistance to linezolid in Staphylococcus aureus,
Staphylococcus cohnii, and Staphylococcus epidermidis (1), but to the
best of our knowledge, they have not been reported in Staphylococcus
hominis so far. We report both 23S rRNA and L3 mutations in lin-
ezolid-resistant S. hominis strains circulating in an intensive care unit
(ICU) of a tertiary care hospital located in Brazil.
From August 2008 to September 2011, three S. hominis strains
exhibiting high-level resistance to linezolid (MIC values of 32 to
64 g/ml) were isolated from blood and catheter cultures from
different inpatients in an intensive care unit. These strains repre-
sented 1.2% of all S. hominis strains isolated in this period at this
institution. All the patients were treated with linezolid (Table 1).
The identification of bacterial strains was performed with the Vi-
tek-2 system (bioMérieux, St. Louis, MO) and according to the
protocol of Hirotaki et al. (2). Antimicrobial susceptibility was
tested using the disk diffusion and broth dilution methods of the
CLSI (3). The presence of the cfr gene and mutations in the do-
main V region of 23S rRNA, rplC, and rplV genes were investi-
gated byPCRas described previously (4), except that the rplD gene
was amplified using the forward primer for rplD and the reverse
primer for rplC. PCR products were sequenced and aligned with
the corresponding nucleotide sequence from linezolid-susceptible
S. hominis strain SK119 (NCBI accession no. 629742). Addition-
ally, a linezolid-susceptible S. hominis strain (6/831) isolated from
a patient hospitalized in the same hospital was also tested for com-
parison purposes. The domain V fragment was digested with the
NheI restriction enzyme, and determination of the clonal related-
ness of strains was carried out by pulsed-field gel electrophoresis
(PFGE) using the restriction enzyme SmaI.
All isolates were clonally related and multidrug resistant but
remained susceptible to vancomycin, teicoplanin, and tetracy-
cline. Two strains, with a linezolidMICof 64g/ml, were found to
have G2576T in 23S rRNA andmutations Gly139Arg/Met156Thr
in the L3 protein, whereas one strain, with aMIC of 32g/ml, had
Phe147Ile in the L3 protein, in addition to G2576T. The incom-
plete digestion of domain V with NheI suggested the presence of
fragments with both the G2576Tmutant and wild-type sequences
in all linezolid-resistant S. hominis strains. Mutations in the pro-
teins L4 and L22, as well as the presence of the cfr gene, were not
identified in any isolates.
Previous studies have already reported Phe147Ile, Gly139Arg,
and Met156Thr in the L3 protein of other species (5, 6). The lin-
ezolid MIC of the S. hominis strain 35/1228 was similar to those
reported by Kosowska-Shick et al. (5) for two S. epidermidis
strains that also had Phe147Ile simultaneously with G2576T in
23S rRNA (wild-type L4 and cfr negative). The combination of
Gly139Arg and Met156Thr substitutions in L3 has not been re-
ported previously, especially accompanied by the G2576T muta-
tion, whichwas present inmultiple copies of the 23S rRNAgene of
the S. hominis strains evaluated in this study. However, these mu-
tations were not able to confer high levels of linezolid resistance in
S. hominis. A linezolid-resistant S. aureus strain (wild-type L4 and
L22 proteins and cfr negative), which also had G2576T and only
Gly139Arg in L3, displayed a higher linezolid MIC (256 g/ml)
(6) than the S. hominis strains of this study (64 g/ml) with both
the Gly139Arg and Met156Thr mutations.
The identificationof these samemutations in theL3proteinof the
linezolid-resistant S. hominis strains strengthens the role of these sites
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TABLE 1 Demographic data and antimicrobial susceptibility profiles of the linezolid-resistant S. hominis clinical strains
Strain ICUa
Culture
date
(mo/yr)
Culture
day/duration of
treatment
(days)
Clinical
sample
cfr
gene
Mutation(s)
Resistance profileb
MIC (g/ml)
CIP TEC SXT AMK GEN ERY CLI TET CHL23S rRNA L3 protein LZD VAN OXA
S. hom..6/831c Yes 09/10 Blood culture Absent None (wtd) None (wt) 1 4 256 R S S S R R R S R
S. hom..35/1228 Yes 08/10 42/68 Catheter tip Absent G2576T Phe147Ile 32 4 256 I S R I R R R S R
S. hom..41/1283 Yes 04/11 38/30 Blood culture Absent G2576T Gly139Arg/Met156Thr 64 4 256 R S R R R R R S R
S. hom..43/257 Yes 09/11 39/41 Catheter tip Absent G2576T Gly139Arg/Met156Thr 64 4 256 I S R R R R R S R
a ICU, intensive care unit.
b LZD, linezolid; VAN, vancomycin; OXA, oxacillin; CIP, ciprofloxacin (5 g); TEC, teicoplanin (30 mg); SXT, trimethoprim-sulfamethoxazole (1.25/23.75 mg); AMK, amikacin
(30 mg); GEN, gentamicin (10 mg); ERY, erythromycin (15 mg); CLI, clindamycin (2 mg); TET, tetracycline (30 mg); CHL, chloramphenicol (30 mg); R, resistant; S, susceptible; I,
intermediate.
c Strain S. hom..6/831 corresponds to a linezolid-susceptible strain isolated from a patient hospitalized in the same hospital.
d wt, wild type.
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in the acquisition of linezolid resistance in Staphylococcus spp., al-
though the presence of G2576T in the 23S rRNA genemakes it diffi-
cult to determine the exact role of L3 mutations in conferring the
elevated linezolidMIC values shown by these clinical strains.
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